FDAnews
www.fdanews.com/articles/120854-onyx-initiates-phase-i-study-for-advanced-solid-tumors

Onyx Initiates Phase I Study for Advanced Solid Tumors

September 29, 2009
Onyx Pharmaceuticals, Inc. announced that it has begun enrolling patients in a Phase 1 study of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, as a potential treatment for advanced solid tumors.
News Blaze